Anil Dhuna, MD
Neurology · West Burlington, IANPI 1912019118
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 26.9% of the total.
Across 98 payments — averaging $34.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$919
- AbbVie$348
- SK Life Science, Inc.$265
- Biogen$216
- Lundbeck LLC$216
- Novartis$196
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,412100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 11 | $919 |
| AbbVie(2 entities) | 9 | $348 |
| SK Life Science, Inc. | 4 | $265 |
| Biogen | 3 | $216 |
| Lundbeck LLC | 7 | $216 |
| Novartis | 10 | $196 |
| Teva Pharmaceuticals USA, Inc. | 17 | $187 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $139 |
| Bristol Myers Squibb | 6 | $117 |
| E.r. Squibb & Sons, L.L.C. | 1 | $92 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $91 |
| Jazz Pharmaceuticals Inc. | 3 | $73 |
| Abbott | 3 | $70 |
| Itamar Medical Inc | 1 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Argenx US, Inc. | 2 | $48 |
| Livanova USA, Inc. | 2 | $47 |
| Acadia Pharmaceuticals Inc | 2 | $43 |
| EMD Serono, Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Eisai Inc. | 1 | $28 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Philips North America LLC | 1 | $20 |
| Harmony Biosciences LLC | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Amgen | 1 | $14 |
| Adamas Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$615
- Inspire Upper Airway Stimulation System$224
- XCOPRI$125
- NURTEC ODT$125
- BOTOX$109
How this compares
$3,412 in reported general payments places this provider in the 80th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex (4 Pack)Interferon Beta-1a | 12 | $97,599 |
| Nurtec OdtRimegepant Sulfate | 23 | $35,258 |
| Emgality PenGalcanezumab-Gnlm | 29 | $28,111 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $19,138 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $12,179 |
| XcopriCenobamate | 11 | $10,721 |
| Pregabalin | 105 | $6,998 |
| Baclofen | 80 | $4,942 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 250 | $4,003 |
| Carbamazepine | 50 | $2,777 |
| Levetiracetam | 87 | $2,659 |
| Lacosamide | 34 | $2,464 |
| Gabapentin | 125 | $1,940 |
| Ropinirole Hcl | 69 | $1,566 |
| Levetiracetam ErLevetiracetam | 36 | $1,400 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $216 | $97,59912 claims |
| SK Life Science, Inc.Xcopri | $265 | $10,72111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 132 neurology providers in Iowa.
Other neurology in West Burlington
- Rahul KhannaWest Burlington$38K
- Aneesh NeekhraWest Burlington$1K
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Winthrop RiskCedar Rapids$136K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Scott GeislerCedar Rapids$87K
- Douglas NathansonIowa City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.